Method for raising hdl cholesterol levels
1997
Abstract
Compounds which are PPAR delta agonists are described. These compounds are useful for raising high density lipoprotein (HDL) plasma levels in mammals and for preventing, halting or slowing the progression of atherosclerotic cardiovascular diseases and related conditions and disease events. PPAR delta agonists can be administered alone or in combination with additional active agents such as LDL-lowering agents
Details
Title
Method for raising hdl cholesterol levels
Author(s)
Leibowitz, M.D. ; Berger, J.P. ; Moller, D.E. ; Auwerx, J. ; Berger, G.D.
Date
1997
Note
Applicant(s): Merck & Co Inc [Us], Leibowitz Mark D, Berger Joel P, Moller David E, Auwerx Johan, Berger Gregory D
Alternative title(s) : (de) Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit (fr) Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite (en) Heterocyclic derivatives as antidiabetic and antiobesity agents
Alternative title(s) : (de) Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit (fr) Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite (en) Heterocyclic derivatives as antidiabetic and antiobesity agents
Other identifier(s)
EPO Family ID: 27583073
Patent number(s)
CA2244836 (C)
DE69735442 (T2)
ES2258799 (T3)
DE69735442 (D1)
AT319440 (T)
DE69733154 (T2)
EP0948327 (B1)
ES2241036 (T3)
DE69733154 (D1)
AT293963 (T)
EP1011651 (B1)
DE69728267 (T2)
DE69723680 (T9)
ES2217392 (T3)
DE69720429 (T9)
DE69728267 (D1)
DE69723680 (T2)
AT262334 (T)
ES2202582 (T3)
EP0904079 (B1)
DE69720429 (T2)
ES2194179 (T3)
DE69723680 (D1)
AT245622 (T)
EP0888278 (B1)
DE69720429 (D1)
AT236137 (T)
EP0882029 (B1)
EP0948327 (A4)
US6515015 (B1)
JP2002515865 (A)
JP2002503203 (A)
JP2002503202 (A)
JP2001511767 (A)
US6160000 (A)
US6090836 (A)
US6090839 (A)
AU721452 (B2)
EP1011651 (A1)
EP1011651 (A4)
AU719663 (B2)
AU719146 (B2)
JP2000504021 (A)
US6020382 (A)
AU712607 (B2)
EP0948327 (A1)
AU708055 (B2)
EP0888278 (A4)
EP0904079 (A4)
EP0904079 (A1)
US5859051 (A)
EP0888278 (A1)
EP0882029 (A1)
US5847008 (A)
ZA9700824 (B)
AU5615298 (A)
CA2275394 (A1)
WO9827974 (A1)
AU1856997 (A)
AU1856397 (A)
AU2115997 (A)
AU2250797 (A)
AU1858197 (A)
WO9728149 (A1)
WO9728137 (A1)
CA2245529 (A1)
WO9728115 (A1)
CA2245524 (A1)
WO9727857 (A1)
CA2244831 (A1)
WO9727847 (A1)
CA2244836 (A1)
GB9705857 (D0)
GB9604231 (D0)
GB9604232 (D0)
GB9604233 (D0)
GB9604234 (D0)
DE69735442 (T2)
ES2258799 (T3)
DE69735442 (D1)
AT319440 (T)
DE69733154 (T2)
EP0948327 (B1)
ES2241036 (T3)
DE69733154 (D1)
AT293963 (T)
EP1011651 (B1)
DE69728267 (T2)
DE69723680 (T9)
ES2217392 (T3)
DE69720429 (T9)
DE69728267 (D1)
DE69723680 (T2)
AT262334 (T)
ES2202582 (T3)
EP0904079 (B1)
DE69720429 (T2)
ES2194179 (T3)
DE69723680 (D1)
AT245622 (T)
EP0888278 (B1)
DE69720429 (D1)
AT236137 (T)
EP0882029 (B1)
EP0948327 (A4)
US6515015 (B1)
JP2002515865 (A)
JP2002503203 (A)
JP2002503202 (A)
JP2001511767 (A)
US6160000 (A)
US6090836 (A)
US6090839 (A)
AU721452 (B2)
EP1011651 (A1)
EP1011651 (A4)
AU719663 (B2)
AU719146 (B2)
JP2000504021 (A)
US6020382 (A)
AU712607 (B2)
EP0948327 (A1)
AU708055 (B2)
EP0888278 (A4)
EP0904079 (A4)
EP0904079 (A1)
US5859051 (A)
EP0888278 (A1)
EP0882029 (A1)
US5847008 (A)
ZA9700824 (B)
AU5615298 (A)
CA2275394 (A1)
WO9827974 (A1)
AU1856997 (A)
AU1856397 (A)
AU2115997 (A)
AU2250797 (A)
AU1858197 (A)
WO9728149 (A1)
WO9728137 (A1)
CA2245529 (A1)
WO9728115 (A1)
CA2245524 (A1)
WO9727857 (A1)
CA2244831 (A1)
WO9727847 (A1)
CA2244836 (A1)
GB9705857 (D0)
GB9604231 (D0)
GB9604232 (D0)
GB9604233 (D0)
GB9604234 (D0)
Laboratories
NCEM
Record Appears in
Scientific production and competences > SV - School of Life Sciences > IBI-SV - Interfaculty Institute of Bioengineering > NCEM - Nestlé Chair in Energy Metabolism
Work outside EPFL
Patents
Work outside EPFL
Patents
Record creation date
2009-04-21